Skip to main content
. 2019 Aug 21;9(22):6485–6500. doi: 10.7150/thno.34429

Figure 3.

Figure 3

Intratumoral co-delivery of dox with immune adjuvants boosts lymphocyte influx in the tumor microenvironment. At day 8, mice with TC-1 tumors received a single intratumoral injection of either PBS (mock control) or NP(dox+pIC+R848+MIP3α). Ten days later, the tumors were resected and analyzed by flow cytometry: (A) Representative flow cytometry plot showing CD45.2 cells in a mock (PBS) or treated tumor. The box and whiskers plot depicts n = 4 from one representative out of two independent experiments (p=0.0286). (B) Representative flow cytometry plot showing CD3+ cells in a mock (PBS) or treated tumor. The box and whiskers plot depicts n = 4 from one representative out of two independent experiments (p=0.0286). (C) Representative flow cytometry plot showing CD4+ T cells in a mock (PBS) or treated tumor. The box and whiskers plot depicts n = 4 from one representative out of two independent experiments (p=0.0286). (D) Representative flow cytometry plot showing CD8+ T cells in a mock (PBS) or treated tumor. The box and whiskers plot depicts n = 4 from one representative out of two independent experiments (p=0.1143; n.s.). (E) Different cell types within the myeloid population analyzed in the tumor is depicted upon mock treated (PBS) tumors or treated tumors. n = 4 from one representative out of two independent experiments. (F) Different cell types within the myeloid population analyzed in the spleen is depicted upon mock treated (PBS) tumors or treated tumors. n = 4 from one representative out of two independent experiments. Statistics were calculated using a two-tailed Mann Whitney test. Statistical differences were considered significant at p < 0.05. * = p < 0.05; ** p = < 0.01; *** p < 0.001. Data plotted are presented as min to max.